EphB receptor tyrosine kinases and ephrin-B ligands regulate several types of cell-cell interactions during brain development, generally by modulating the cytoskeleton. EphB/ephrinB genes are expressed in the developing neural tube of early mouse embryos with distinct overlapping expression in the ventral midbrain. To test EphB function in midbrain development, mouse embryos compound homozygous for mutations in the EphB2 and EphB3 receptor genes were examined for early brain phenotypes. These mutants displayed a morphological defect in the ventral midbrain, specifically an expanded ventral midline evident by embryonic day E9.5-10.5, which formed an abnormal protrusion into the cephalic flexure. The affected area was comprised of cells that normally express EphB2 and ephrin-B3. A truncated EphB2 receptor caused a more severe phenotype than a null mutation, implying a dominant negative effect through interference with EphB forward (intracellular) signaling. In mutant embryos, the overall number, size, and identity of the ventral midbrain cells were unaltered. Therefore, the defect in ventral midline morphology in the EphB2;EphB3 compound mutant embryos appears to be caused by cellular changes that thin the tissue, forcing a protrusion of the ventral midline into the cephalic space. Our data suggests a role for EphB signaling in morphological organization of specific regions of the developing neural tube.
Introduction
EphB receptor tyrosine kinases, together with their membrane-anchored ephrin-B ligands, transduce bidirectional signals upon cell-cell interactions and are involved in many developmental processes. Among the most studied functions for the Eph/ephrin family are axon guidance, neural crest cell migration, and neural tube patterning (Coulthard et al., 2002; Wilkinson, 2001) . The common aspect of these functions is that Eph/ephrins participate in controlling cell and axon growth cone migration events by transducing signals that affect cytoskeletal dynamics. Consistent with their regionalized activities, EphB and ephrin-B genes have specific expression patterns in the embryo. For example, EphB2 is more highly expressed in the dorsal blastomere than the ventral blastomere, and in fact, functions to dorsalize Xenopus embryos (Tanaka et al., 1998) . Later, EphB expression in the developing hindbrain alternates with ephrin-B expression in rhombomeres, functioning in boundary formation Xu et al., 1999) . Finally, during axon pathfinding events, the midline crossing of anterior commissure fibers in the forebrain are dependent upon EphB2 and ephrin-B2 Henkemeyer et al., 1996) . Thus, depending on the time of development and the area of expression, EphB/ephrin-B signaling can function in various aspects of cell interactions.
While EphB2 expression has been shown to be prominent in the early ventral midbrain (Henkemeyer et al., 1994 , the functions of this receptor have not yet been defined in this region of the neural tube. We therefore studied mouse embryos deficient in EphB2 and the related EphB3 receptor and present evidence that these 
Results

EphB2 and EphB3 are required for normal midbrain morphology
We examined mouse embryos with mutations in the EphB2 and EphB3 genes, which are two of the five known mammalian EphB receptors. In general, each EphB receptor can bind any of the three known ephrin-B ligands . We limited our analysis to E9.5 and E10.5 as we were interested in initial axon tract formation. We have not examined embryos at later stages. EphB2 mutations included a null allele in which EphB2 is completely deleted (EphB2 K ), or an insertion mutation in which the intracellular kinase domain and C-terminal tail of EphB2 has been replaced with beta galactosidase (EphB2 lacZ ) resulting in the synthesis of a truncated EphB2-bgal fusion protein . Because EphB2 and EphB3 are functionally redundant in many instances , both EphB2 mutations were examined in a EphB3 null background (EphB3 K/K ). The EphB2 lacZ encoded EphB2-bgal fusion protein is designed to act dominantnegatively through two mechanisms. It may oligomerize with other EphB receptors to disrupt intracellular signaling. Additionally, the EphB2-bgal fusion protein may sequester ephrins with its intact extracellular ligand-binding domain.
In an initial search for an axon guidance phenotype, we first labeled pioneer axon patterns using whole mount labeling with neuronal antibodies as well as axon tracers. However, axon outgrowth and tract formation at E9.5 and E10.5 was indistinguishable from wildtype embryos (data not shown). Normal tracts included the medial longitudinal fasciculus, oculomotor nerve, and mammilotegmental tract, all of which originate in and grow through the ventral regions that express EphB2 (expression shown below).
However, a role for EphB signaling in ventral midbrain development was apparent from midbrain morphology. An initial analysis of mutant embryos was carried out in a blind fashion, in which we sorted collections of embryos into distinct groups based on their midbrain morphology. We arranged a series based on increasingly severe phenotypes (Fig. 1) , and then genotyped the embryos. EphB3 K/K embryos appeared as wildtype (Fig. 1A,B) . Combining EphB3 mutations with EphB2 mutations resulted in visible phenotypes. Although embryos carrying one EphB2 knockout allele (EphB2 K/C ;EphB3 K/K ) still appeared wildtype (Fig. 1C) , EphB2 K/K ;EphB3 K/K double homozygotes exhibited an abnormal expansion of the ventral midbrain into the space created by the cephalic flexure (Fig. 1D) (Fig. 1F) . The fact that the EphB2 lacZ/lacZ ;EphB3
phenotype was more severe than the double null suggests a dominant negative effect of the EphB2-bgal fusion protein, perhaps through interference with a third, as yet unidentified EphB receptor. In conclusion, an allelic series of EphB2;EphB3 mutant embryos suggests that EphB intracellular signaling is important for normal development of the ventral midbrain. This EphB function is regionspecific since other regions of the brain had normal morphology.
EphB2 and ephrin-B3 expression overlaps in the ventral midbrain
To begin to understand the basis for the ventral midbrain phenotype associated with the EphB2;EphB3 double mutants, we examined EphB and ephrinB expression in the midbrain. We started by establishing the expression pattern of EphB2 in wildtype E9.5 and E10.5 embryos. The expression pattern of EphB2 was revealed by two different methods. First, an in situ hybridization probe against EphB2 was used on wildtype E9.5 and E10.5 embryos. In E10.5 embryos, EphB2 transcripts were limited to ventral midbrain and ventral forebrain ( Fig. 2A) . The same pattern was visible in E9.5 embryos but was much fainter (not shown). Secondly, to confirm the pattern of protein expression, EphB2 lacZ/C embryos were examined. In these embryos, staining with the b-gal substrate X-gal revealed strong expression of the EphB2-bgal fusion protein in the ventral midbrain and forebrain in a pattern identical to the in situ pattern (Fig. 2B) . Sections through midbrain confirmed expression of EphB2 in ventral midbrain, encompassing the ventral midline and extending laterally (Fig. 2C,D) . The expression was limited to neuroepithelial cells and includes the cells of the midline. The nIII motor neurons, which originate lateral to the midline, were within the EphB2 expression region, although they did not express EphB2 mRNA (Fig. 2D ). This result is interesting in light of the protein expression, using either antibodies for wild-type EphB2 protein (Henkemeyer et al., 1994) or via X-gal labeling for EphB2-bgal fusion protein , in the oculomotor axons at this same age. Thus, the midbrain and forebrain express EphB2 in a ventrallyrestricted domain that includes the neuroepithelium of the midline. To compare EphB3 expression, we attempted but failed in both in situ hybridization and antibody labeling approaches. Previous studies have shown that ventral midbrain expresses high levels of both EphB2 and EphB3 at this stage of development (Baker and Antin, 2003; Becker et al., 1994; Ciossek et al., 1995; Henkemeyer et al., 1994 ).
EphB receptors have three possible ligands: ephrin-B1, ephrin-B2 and ephrin-B3 (Brambilla et al., 1996; Drescher, 1997) . Using in situ hybridization with probes against each transcript, only ephrin-B3 was expressed in the ventral midbrain (not shown). To confirm the expression of ephrin-B3 in the ventral midbrain midline cells, we used an ephrin-B3 mutation which carries a lacZ reporter (Yokoyama et al., 2001) . The ephrin-B3 lacZ/C embryos were X-gal reacted, confirming the expression of ephrin-B3 in the ventral midbrain and in the nIII motor neurons (Fig. 2E) . Comparison of the EphB2 and ephrin-B3 patterns revealed that the expression of ephrin-B3 overlapped with EphB2 in the most ventral midline region and underlying the motor neurons, but there was a zone lacking ephrin-B3 expression medial to the motor neurons. The overlapping expression of EphB2 and ephrin-B3 in the ventral midbrain contrasts with other neural tube regions, where previous reports describe complementary expression patterns between Eph receptors and their ligands in early development (Becker et al., 1994; Gale et al., 1996; Holder and Klein, 1999) . The overlapping expression suggests potential EphB2/ephrin-B3 inter and intracellular signaling in the ventral midbrain midline.
Mice embryos lacking EphB2 and EphB3 have an expanded ventral midbrain midline
As shown in Fig. 1 , the gross morphology of the neural tube in EphB2;EphB3 compound mutant embryos was altered. In wildtype embryos, the cephalic flexure is formed by a smooth curve of the neural tube leaving a rounded open space between the ventral forebrain and the ventral midbrain (Fig. 3A) . In E9.5 (not shown) and E10.5 mutant embryos, the cephalic flexure appeared as a sharp angled bend (Fig. 3B ) apparently due to an expansion of the ventral midbrain. To further characterize the midbrain defect of these embryos, the embryos were sectioned transversely , showed increased ventral midbrain expansion as compared to EphB2
K/K compound homozygotes had the most severe ventral midbrain expansion.
through the midbrain. These sections revealed an expanded ventral midline in the mutants, with a prominent thinning of the ventral midline (compare Fig. 3C with D). Thus, this thinned and expanded region accounts for the tissue which projects ventrally into the cephalic flexure space. Despite EphB2 expression in the forebrain ( Fig. 2A ,B) only the midbrain showed an obvious defect, implying that EphB2 and EphB3 in ventral midbrain are functioning in a different capacity than in the forebrain at this stage. The gross morphological defect suggests that EphB2 and EphB3 function in ventral midline morphology of the early midbrain.
Mutations in ephrin-B3 do not disrupt midbrain morphology
Since ephrin-B3 was detected in the ventral midbrain, we also examined ephrin-B3 mutant embryos. Two types of ephrin-B3 mutants were examined: ephrin-B3 K/K , in which ephrin-B3 has been completely knocked out, or mutants in which the cytoplasmic signaling domain has been replaced with beta-galactosidase coding sequence, ephrin-B3 lacZ (Yokoyama et al., 2001) In our analysis we looked at 89 embryos varying in age from E9.5 to E11. We examined the embryos for gross morphology of the ventral midbrain, where again our analysis of phenotype was blinded to genotype. The strong phenotype seen in EphB2;EphB3 mutants was not observed for homozygous mutants of either ephrin-B3 mutant allele. Although some embryos had mild alterations in ventral midbrain morphology, there was no consistent difference between ephrin-B3 mutants and wildtype embryos. The lack of midbrain phenotype suggests that EphB signaling in the ventral midbrain is not wholly dependent on ephrin-B3, and may involve other ligands or receptor mechanisms. 
yellow). nIII neurons overlie EphB2
C region, but do not express EphB2 mRNA. (E) ephrin-B3 expression in midbrain ventral midline and in nIII clusters via X-gal staining of ephrin-B3 lacZ/C embryo. Arrowheads denote boundary of ephrin-B3 midline expression.
Cell proliferation is normal in the ventral midbrain of EphB2;EphB3 mutants
In EphB2;EphB3 mutant embryos, the cause of the expansion of the ventral midbrain could result from several different mechanisms. For example, an increase in the number of cells in the ventral midbrain would cause an expansion. Increased cell number could result from increased mitosis, decreased apoptosis, or cell immigration. Each of these processes occurs normally in development, and if altered in the ventral midbrain, could explain the expansion seen in EphB2;/EphB3 mutant embryos. Another possibility is change in cell identity. The ventral cells could be responding to altered patterning signals in the absence of EphB2 signaling, and thereby taking on a new identity, for example a more dorsal identity. A change in cell identity could result in a new cell shape thus changing the morphology of the ventral field of cells. We tested each of these possibilities in EphB2 lacZ/lacZ ;EphB3 K/K embryos. We performed cell counts of the ventral midline cell population. To count the midline cells, flanking borders first had to be determined. The motor neurons, nIII, marked by expression of Islet1, were used as lateral boundaries for cell counting. We considered the possibility that the nIII clusters might be changed in the EphB2;/EphB3 mutant embryos. For this reason, the nIII clusters of four embryos, two wildtype and two mutant embryos, were counted and compared. The number of nIII cells varied from section to section, but the total number of nIII neurons in each embryo was similar between the two genotypes (data not shown). This analysis suggests that the ventral expansion does not affect the development of the motor neuron cell bodies, and that they are a consistent lateral boundary for cell counting of the ventral midline. The number of ventral midline cells was counted in the anterior half of the midbrain (the region containing Islet1
C nIII neurons at this stage) of two wildtype embryos and two mutant embryos. All sections were first antibody labeled against Islet1, and then DAPI was used to highlight the cell nuclei for counting (Fig. 4A,B) . The cells of the midbrain ventral midline between the motor neuron clusters were counted, graphed, and statistically analyzed. The total number of ventral midline cells was not significantly different between wildtype and mutant embryos (Fig. 4C) . At this stage of development the neuroepithelium is one cell layer thick. A single cell stretches from the ventricular (lumen side) to the pial surface. The nuclei appear pseudostratified as they are in varying positions between these two surfaces. In EphB2 lacZ/lacZ ;EphB3 K/K embryos the nuclei appear further apart, not as closely packed, however, the same number of nuclei, therefore cells, occupy the same area.
To confirm that proliferation rates are not changed in mutant embryos, we also labeled ventral midbrain sections for S-phase cells with bromodeoxyuridine (BrdU) and M-phase cells with phospho-histone3 antibody. Neither method showed differences between wildtype and mutant embryos (data not shown). Thus, the expansion of the midbrain ventral midline is not due to an increased number of cells in the ventral midline. Altogether this data implies EphB signaling does not regulate ventral midline morphology through regulation of cell number.
2.6. The cross-sectional area of the ventral midline of the midbrain is retained in EphB2;EphB3 mutants
Since the cell number in the ventral midbrain was not significantly different between EphB2 lacZ/lacZ ;EphB3
and wildtype embryos, we examined the possibility that the dimensions of individual cells are altered in the mutants.
As stated above, the neuroepithelium consists of a single layer of columnar cells, stretched between the pial and ventricular surfaces, with the cell body suspended between the pial and ventricular attachment points. Thus the length of the cells determines the thickness of the neuroepithelium, while the cell body volume determines the medio-lateral extent of the tissue sheet. It is evident that the length of the ventral midline cells decreased in the mutants, since the mutant neuroepithelium was noticeably thinner (Fig. 3C,D and Fig. 4A,B) . As an indirect measure of cell body volume, we determined the average area from sections of the ventral midbrain from both wildtype and mutant embryos. As for the cell counting above, analysis of area focused on the region ventral to the nIII clusters and in the anterior half of the midbrain (Fig. 4A,B) , as this was the region most strongly affected. The area of the ventral midline is not significantly increased in mutant embryos compared to wildtype (Fig. 4D) . We also counted the number of nuclei between the ventricular and pial surfaces. This number represents an approximation of the spatial arrangement of the cells along the dorsal-ventral axis. Each neuroepithelial cell is attached to both surfaces, however, due to the pseudostratified nature, the nuclei appear stacked (see Fig. 3C,D) . We chose a position, 60% of the way from the nIII cell body clusters towards the ventral midline within the affected area of the EphB2 lacZ/lacZ embryos, but outside the center of the midline. In the mutants, the number of nuclei was obviously less than in wildtype (average six in mutant vs. nine in wildtype). This data supports the finding that ventral midbrain neuroepithelium is distorted by a proportional thinning in EphB2 lacZ/lacZ embryos. In summary, the neuroepithelium was thinner yet retained the same cross-sectional area. These observations imply that on the cellular level, while the cell lengths decreased, the cell bodies altered their shape proportionately, although this was not examined directly. Therefore, the expansion of the ventral midbrain was not due to increases in cell numbers or volumes, as this would have changed the cross-sectional area, but rather cellular changes that thinned the ventral midbrain tissue.
The identity of the ventral midline cells is not changed in EphB2;EphB3 mutant embryos
A change in cell identity could lead to a change in cell shape, therefore we considered the possibility of a role for EphB signaling in designating the identity of the ventral midbrain midline cells. Using molecular markers for specific populations of cells in the ventral midbrain, we determined the dorsal-ventral position and identity of the affected cell populations.
We used Islet1 and beta-tubulin (TuJ1) antibodies to mark the positions of the nIII cluster relative to the expression boundaries of several dorsal-ventral patterning markers in the EphB2/B3 double mutants. Nkx2.2: Nkx2.2 is a transcription factor defining a population of lateral neural tube cells just dorsal to the TuJ1 C nIII clusters ( Fig. 5A ) (Ericson et al., 1997 (Fig. 5B) . Hnf3b: Hnf3b is a transcription factor expressed by ventral cells (Marti et al., 1995) , through the midline laterally to the neuroepithelial cells adjacent to the nIII clusters. Therefore Hnf3b expression included the affected ventral midline cells, as well as cells located more laterally (Fig. 5C ). This expression was maintained in mutant embryos (Fig. 5D) . P84: P84 is a cell surface marker expressed most strongly by floorplate cells in the hindbrain and spinal cord, but has some expression in the midbrain ventral midline at E10.5 ( Fig. 5E ) (Chuang and Lagenaur, 1990) . The expression of P84 in mutant embryos was not only retained in the ventral midline cells, but appears to closely define the affected population. Specifically, in the mutant, the P84 C region is expanded yet the P84-negative (still Hnf3b C ) region that extends laterally to the Islet1 C cells is similar in size to wildtype (Fig. 5F ). Shh, Pax6: We also examined the expression of two other markers: Shh, an extracellular signaling protein with midbrain expression extending from the midline laterally past the nIII neurons (Ericson et al., 1995) , and Pax6, a transcription factor with expression limited to more lateral regions (Stoykova and Gruss, 1994) . Neither marker had altered expression in mutant embryos (data not shown), suggesting that regions outside of the ventral midline were not affected.
These molecular markers show that the ventral midline cells express the combination of P84, Hnf3b, and Shh (in addition to EphB2, EphB3 and ephrin-B3). Of particular note is that the expression domain of P84 closely matches the affected population of ventral cells. Therefore, although the morphology of the midline tissue has changed, tissue identity appears unchanged in EphB mutant embryos.
Discussion
A striking feature of Eph receptors and ephrin ligands is the regional-specificity of their expression patterns, implying region-specific functions in development. In this study, we characterized the expression patterns of EphB2 receptor and ephrin-B3 ligand in the midbrain of the early mouse embryo and investigated the genetic functions of EphB2 and EphB3 signaling in midbrain development. We examined mutant mice carrying two null alleles of EphB3 and varying combinations of two different EphB2 alleles. We found that embryos carrying two alleles of EphB2 lacZ in combination with EphB3 K/K had the most severe midbrain morphological defect. Furthermore, we found that the defect was not the result of an increased number of midline cells, an increased cross-sectional area of the tissue, nor a change of identity of these cells. Therefore, we concluded that EphB mutations cause a change in the overall morphology of the ventral midbrain, where specifically the tissue was proportionally thinner and medio-laterally expanded. This novel capacity of EphB signaling raises several issues for discussion, including functional redundancy of EphB receptors, the potential significance of overlapping Eph and ephrin expression, the dominant-negative activity of the EphB2 lacZ allele, and how these novel EphB functions may relate to known Eph/ephrin signaling targets.
A midbrain morphological phenotype is evident only when both receptors, EphB2 and EphB3, are genetically altered. Ventral midbrain in wildtype embryos is known to express high levels of both EphB2 and EphB3 at this stage of development (Baker and Antin, 2003; Becker et al., 1994; Ciossek et al., 1995; Henkemeyer et al., 1994) . It is also known that mice homozygous for the EphB3 null allele exhibit agenesis of the corpus callosum at a frequency of 37%, but the adults are viable and long-lived, without any behavioral or developmental abnormalities (see Fig. 1B and ). Based on these findings from previous research, the critical signaling is likely via EphB2. However, the possibility exists that all of the functions we have ascribed to EphB2 could equally apply to EphB3 if redundancy is complete.
Ephrin-B3 is expressed in the ventral midbrain in E9.5 and E10.5 embryos, partially overlapping with EphB2 expression. Interestingly, even though this ligand was the only potential ligand that we could detect in the ventral midbrain, ephrin-B3 mutant embryos did not phenocopy the EphB2;EphB3 mutants. This suggests that EphB signaling in the absence of ephrin-B3 involves other ligands, perhaps other ephrin-Bs expressed below the level of detection or perhaps some other mechanism of receptor activation. It is also possible that the ligand ephrin-A5 may have roles as it is expressed in the midbrain early in development Zarbalis and Wurst, 2000) and has recently been shown to bind and activate EphB2 receptor signaling (Himanen et al., 2004) . Despite the lack of phenotype in ephrin-B3 K/K embryos, overlapping expression pattern of EphB2 and ephrin-B3 is interesting. Usually Eph/ephrins are present in complementary patterns for functions in boundary formation or in axon guidance. In our case, with both receptor and ligand expressed on the same cells, a cell adhesion or pattern formation function seems more likely (Dravis et al., 2004) . Our results indicate that the midbrain defect is restricted to the region of overlapping EphB2/ephrin-B3 expression.
The finding that the EphB2 lacZ/lacZ ;EphB3 K/K double homozygous embryos exhibit the most severe phenotype implies that the cytoplasmic portion of the EphB2 receptor is critical. In other words, ligand binding without receptor signal transduction creates a greater impairment to proper development than lack of receptor altogether. Another implication is that the defect is not the result of a disruption of reverse signaling through ephrin-B3, in which case the most severe phenotype would be seen in EphB2 K/K ;EphB3 K/K double null mutants rather than EphB2 lacZ/lacZ ;EphB3 K/K mutants. This suggests that the EphB2-bgal fusion protein is functioning in a dominantnegative manner, such as interfering with a third Eph receptor present in the ventral midbrain midline cells. If a third Eph receptor exists in the ventral midbrain, it could be partially rescuing ventral midbrain development when both EphB2 and EphB3 are completely missing. This would explain the less severe phenotype observed in these embryos (Fig. 1B-E) . Eph receptor signaling occurs only when receptors are oligomerized through ligand binding (Davis et al., 1994) . Therefore, the potential mechanisms for the dominant negative-activity of the EphB2 lacZ allele include an interfering interaction through the necessary oligomerization of the mutant protein with the hypothetical third EphB receptor, or simply through sequestering a limited supply of ligand, although the lack of phenotype in ephrin-B3 mutants does not support this idea. Dominant-negative functions have been described for EphA7, which with ephrin-A5, usually signals a repulsive cue. However, an EphA7 splice variant produces a truncated receptor, which interacts with full-length receptor and allows adhesion during neural tube closure (Holmberg et al., 2000) . In our case, the signal transduced by EphB receptors in the midline cells is dependent upon the cytoplasmic domain of EphB2.
On the cellular level, an expansion of ventral midbrain could be the result of one of several different mechanisms. An increase in cell number via increased mitosis, decreased apoptosis, or cell immigration would cause the ventral midline to expand. An alteration of any of these processes, which regulate growth and morphology during development, could explain the expansion seen in the EphB2;EphB3 mutant embryos. In this study, we tested all of these possibilities and found they were not significantly altered in EphB2;EphB3 mutants compared to wildtype embryos. These findings lead us to the overall conclusion that the mutant phenotype observed results from specific changes within each cell or in the adhesive relationship between the cells of the ventral midline.
Eph/ephrin signaling could mold tissue morphology through the actin cytoskeleton (Schmucker and Zipursky, 2001; Zimmer et al., 2003) . Much evidence for actin regulation comes from analysis of growth cone repulsion, but other functions attributed to Eph/ephrin signaling may also be mediated via actin cytoskeleton interactions, specifically cell migration and cell adhesion. The cytoplasmic domain of Eph receptors interacts with a myriad of different proteins, many of which are implicated in cytoskeletal regulation (Bruckner and Klein, 1998; Holder and Klein, 1999; Kalo and Pasquale, 1999; Xu and Wilkinson, 1997; Zisch and Pasquale, 1997) . Additionally, the extreme C-terminal tail of EphB2 is bound by PDZ domain proteins which may allow this receptor to interact with a variety of other proteins that may function in cell morphology (Cowan et al., 2000; Hock et al., 1998) . Thus the actin cytoskeleton is a likely target for EphB regulation of ventral midbrain morphology. Furthermore, changes in actin cytoskeleton could affect each individual cell or affect the overall relationship between the cells of the ventral midline.
Eph/ephrin regulation of morphogenesis has been described for several of the EphA and EphB receptors, including epidermal and mesodermal morphogenesis in early embryogenesis (Chan et al., 2001; Chin-Sang et al., 1999; Holder and Klein, 1999 ). An emerging theme is that Eph expression defines fields of cells with shared morphological fate. Evidence in early development of zebrafish supports a role for Eph signaling in patterning of the forebrain (Xu et al., 1996) . An example in later development is in the cerebellum, where Eph receptor expression defines the cell population fated to become a lobe (Rogers et al., 1999) . In the midbrain, EphB2 and ephrin-B3 expression defines a field of cells that may cooperate to maintain the shape of the ventral-most region of the midbrain. This raises the possibility that other Eph receptors may have similar functions, not only in the brain but also in other tissues.
In conclusion, we have described a novel function for EphB2 and EphB3 in neural tube development. We found that midbrain morphology is disrupted in EphB mutant embryos, resulting in an expansion of the ventral midline. The affected cells retained their identity, total overall number, and proximal relationship to each other. We suggest that local regions of the neural tube, such as the ventral midline of the midbrain, may depend on regionspecific EphB signaling to define tissue morphology. The role of EphB signaling in morphological development may also facilitate later developmental functions such as axon outgrowth and targeting, cell migration, and trophic activity.
Experimental procedures
Mice
Embryos were collected from crosses between Eph-B2 lacZ/C ;EphB3 K/K mice or EphB2 K/C ;EphB3 K/K in the CD1 background. Embryos were collected at either embryonic day 9.5 (E9.5) or E10.5. The day of the vaginal plug was designated day E0.5. Embryos were genotyped using PCR . Embryos were stored in 4% paraformaldehyde, 0.1 M phosphate buffer at 4 8C until used for in situ hybridization or antibody labeling.
In situ hybridization
Whole embryos stored in 4% paraformaldehyde, 0.1 M phosphate buffer were washed in PBS three times for 5 min. A dehydration series using methanol:PBT (PBS, 0.1% Triton-X) was applied going from 0:100% in increments of 25%. After two washes at 100% methanol for 5 min each, the series was reversed, rehydrating the embryos and finishing with two washes of 5 min each in 100% PBT. Embryos were then bleached with 6% hydrogen peroxide in PBT for 1 h at RT. Treatment with proteinase K, 20 mg/ml in PBT, was carried out at RT for 5-10 min (this step was minimized or skipped with E9.5 embryos). Proteinase K was inhibited by the addition of glycine, 2 mg/ml in PBS, and followed by refixing in 0.2% gluteraldyhyde in 4% paraformaldehyde. Embryos were then placed in prehybridization buffer (50% formamide, 5XSSC, 50 mg/ml tRNA, 1% SDS, 50 ml/ml heparin) and incubated at 658 for 1-3 h (Wilkinson and Nieto, 1993) . At this stage, digoxigenin labeled RNA probe was added and incubation continued overnight. Probes were transcribed from plasmid containing cDNA from EphB2, ephrinB1, B2 and B3. After overnight incubation, hybridization was continued by washing embryos two times for 30 min at 658in Sol 1 (50% formamide, 5XSSC, 1% SDS) then three times for 5 min in 1:1 mix of Sol 1:Sol 2 (.5 M NaCl, 0.1% Tween-20, 1 mM Tris-HCl pH 7.5) at 658, followed by three times for 5 min in Sol 2 at RT. Finally incubation with RnaseA, 20 mg/ml in Sol 2, at 378 for 30 min was carried out. RNase treatment was followed by two washes for 5 min in Sol 2 at RT and two washes for 30 min in Sol 3 (50% formamide, 5XSSC) at 658. Finally embryos were rinsed three times for 5 min in TBST (.14 M NaCl, 2.7 mM KCl, 25 mM Tris-HCl pH 7.5, 0.1% Tween-20). Embryos were then blocked in 10% heat-treated sheep serum in TBST for 1-3 h. Visualization of the probe was done with anti-digoxigenin antibody conjugated to AP (1:1000, Roche) overnight at RT. Rinses in TBST for a total of 5 h the next morning were followed by a final wash of TBST with 2 mM levamisol for 1 h at RT. Washes of three times for 5 min in NTMT (100 mM NaCl, 100 mM TrisHCl pH 9.5, 50 mM MgCl 2 , 0.1% Tween-20) with 2 mM levamisol were done before adding NBT/BCIP to produce characteristic purple precipitate at site of RNA probe. Embryos were then stored in 4% paraformaldehyde indefinitely.
Embedding and sectioning
Embryos were fixed in 4% paraformaldehyde, 0.1 M phosphate buffer for 1 h (short fix) or up to 2 weeks (long fix). Embryos were rotated for 1 h at room temperature in 5% sucrose, 0.1 M phosphate buffer. The buffer was changed to 15% sucrose in 0.1 M phosphate buffer and the embryos continued rotating at room temperature for at least 6 h or overnight. The embryos were then incubated for 6 h or overnight at 37 8C in 7.5% gelatin, 15% sucrose, 0.1 M phosphate buffer. The same gelatin solution is used for the blocks in which one embryo per block was embedded. The block was frozen by slowly immersing in a slurry of 2-methylbutane and dry ice. The embedded embryos were stored at K20 8C until cryosectioned. Cryosectioning was done at K24 8C. Ten micron thick sections were placed on Superfrost Plus (Fisher) slides and stored at K20 8C until used for immunofluorescence.
Immunofluorescence
Slides with cryosections were placed in warm PBS to melt off the gelatin embedding solution. After briefly drying at RT the sections were rinsed three times for 5 min in PBS. Primary antibody was diluted in blocking solution (PBS, 1% goat serum, 0.1% Triton-X) and applied to the slide. Slides were placed in a humidified chamber overnight at RT. Primary antibody was removed from slide and slide was rinsed three times for 5 min with PBST (1XPBS, 0.1% Triton-X). The appropriate biotinylated IgG (Jackson Laboratory) secondary antibody, used at 1:100 in blocking solution, was applied for 1 h in humidified chamber at RT. Slides were again rinsed three times for 5 min in PBST. Cy2 or Cy3 conjugated Strepavidin (Jackson Laboratory), 1:200 in blocking solution, was applied for 1/2 h in humidified chamber at RT. Slide were rinsed, coverslipped using Prolong Antifade (Molecular Probes) as mounting medium, and stored at K20 8C. Some antibodies required Milk-TST protocol which included a 1 h blocking step before application of primary antibody. The protocol then followed the above steps using TST (10 mM Tris pH7.4, 150 mM NaCl, 0.1% Tween-20) in place of PBST for rinsing, and 4%-Milk TST (TST, 4% w/v dry milk) as blocking solution and for making dilutions of antibodies.
Primary antibodies used in this study were: P84 [mouse, (1:200) Mastick and Andrews,2001) and (1:200) , Upstate Biotechnology). Shh, Pax6, and PH-3 were used with Milk-TST protocol.
Cell counting
Using 10 mm cryostat sections of E10.5 midbrain, the nuclei of all cells were DAPI labeled. DAPI labeling was achieved by using 1 mg/ml in PBS and applying to cryosections for 1 min followed by three rinses for 5 min each in PBS. Sections were also labeled with Islet1-Cy3 as described above. In Adobe Photoshop, two images of the same section-one with Islet1 visualized and one with cell nuclei visualized via DAPI-were arranged side by side. Lines delineating the ventral most Islet1Ccell were drawn on the Islet1 image and transferred to the DAPI image. In this way the boundaries were moved to the image with the cell nuclei visualized for counting. All nuclei within the lines spanning the ventral midline were counted. This process was repeated for each section of the ventral midbrain for two wildtype and two EphB2 lacZ/lacZ ; EphB3 K/K embryos. Approximately the anterior half of each midbrain was counted. After counting, the numbers were arranged in order of the midbrain section from anterior to posterior and graphed. An average was taken for the midbrain ventral midline of mutant and wildtype. The averages were compared and statistically analyzed in Excel using the student t-test.
Ventral midline measuring: Measuring the ventral midline total area followed the same procedure described for counting with the exception that instead of counting the total number of cell nuclei between the ventral most Islet1C cells, the area was physically cut out of the paper and weighed. Standards of 10 cm 2 and 10 mm 2 were used to establish a scale for the Y-axis. Data points were graphed using the X-axis as representing anterior toward posterior of the ventral midbrain sections. Using Excel the average area was calculated and compared between wildtype and EphB2 lacZ/lacZ ;EphB3 K/K embryos. Statistical analysis was done using the Student t-test.
